CIGB-470

CIGB-470 is an active immunotherapy candidate developed by the **Cuban Center for Genetic Engineering and Biotechnology (CIGB)** for the treatment of age-related macular degeneration (AMD). It is a therapeutic vaccine designed to elicit an endogenous polyclonal antibody response against **Vascular Endothelial Growth Factor (VEGF)**. By targeting VEGF, CIGB-470 aims to inhibit the pathological neoangiogenesis and vascular leakage characteristic of neovascular (wet) AMD. This approach represents an alternative to standard-of-care passive immunotherapy (intravitreal anti-VEGF monoclonal antibodies), potentially offering a more sustained therapeutic effect and reducing the frequency of clinical interventions required for patients.